Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jun 5, 2023. (Total: 217663Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 11 (of 11 Records)

Query Trace: Pancreatic Neoplasms and CDA[original query]
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jan 16 (1): 320-9.
Okazaki Taro, Javle Milind, Tanaka Motofumi, Abbruzzese James L, Li Dongh
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Clinical pharmacokinetics 2010 Aug 49 (8): 549-58.
Sugiyama Emiko, Kaniwa Nahoko, Kim Su-Ryang, Hasegawa Ryuichi, Saito Yoshiro, Ueno Hideki, Okusaka Takuji, Ikeda Masafumi, Morizane Chigusa, Kondo Shunsuke, Yamamoto Noboru, Tamura Tomohide, Furuse Junji, Ishii Hiroshi, Yoshida Teruhiko, Saijo Nagahiro, Sawada Jun-Ic
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
Cancer 2010 Nov 116 (22): 5325-35.
Tanaka Motofumi, Javle Milind, Dong Xiaoqun, Eng Cathy, Abbruzzese James L, Li Dongh
Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
The pharmacogenomics journal 2012 Oct 12 (5): 395-403.
Farrell J J, Bae K, Wong J, Guha C, Dicker A P, Elsaleh
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Investigational new drugs 2012 Jun 30 (3): 1164-74.
Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J
Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
Hepato-gastroenterology 0 59 (117): 1609-13.
Kasuya Kazuhiko, Tsuchida Akihiko, Nagakawa Yuichi, Suzuki Yoshiaki, Suzuki Minako, Aoki Tatsuya, Abe Yuta, Shimazu Motohide, Itoi Takao, Sofuni Atsus
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Pharmacogenomics 2013 Jul 14 (9): 1047-51.
Serdjebi Cindy, Seitz Jean-François, Ciccolini Joseph, Duluc Muriel, Norguet Emmanuelle, Fina Frédéric, Lacarelle Bruno, Ouafik L'houcine, Dahan Laetit
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). GWAS Catalog
Pharmacogenetics and genomics 2019 Mar .
Innocenti Federico, Jiang Chen, Sibley Alexander B, Denning Stefanie, Etheridge Amy S, Watson Dorothy, Niedzwiecki Donna, Hatch Ace J, Hurwitz Herbert I, Nixon Andrew B, Furukawa Yoichi, Kubo Michiaki, Crona Daniel J, Kindler Hedy L, McLeod Howard L, Ratain Mark J, Owzar Kour
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
British journal of clinical pharmacology 2018 Dec .
Cohen R, Preta L H, Joste V, Curis E, Huillard O, Jouinot A, Narjoz C, Thomas-Schoemann A, Bellesoeur A, Tiako Meyo M, Quilichini J, Desaulle D, Nicolis I, Cessot A, Vidal M, Goldwasser F, Alexandre J, Blanchet
Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer.
BioMed research international 2021 10 2021 9949272.
Ma Zuyi, Li Zhenchong, Ma Zuguang, Zhou Zixuan, Zhuang Hongkai, Liu Chunsheng, Huang Bowen, Zou Yiping, Zheng Zehao, Yang LinLing, Gong Yuanfeng, Huang Shanzhou, Zhou Qi, Zhang Chuanzhao, Hou Baoh
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
The pharmacogenomics journal 2021 Jan .
Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marz
TOP